| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Chengcheng Pu, Bingjie Huang, Tianhang Zhou, Zhang Cheng, Yi Wang, Chuan Shi, Xin Y. Gender Differences in the First-Year Antipsychotic Treatment for Chinese First-Episode Schizophrenia. Neuropsychiatric disease and treatment. vol 16. 2020-12-31. PMID:33364771. |
to investigate the gender differences in the efficacy and side effects of three frequently used antipsychotic medicines (risperidone, olanzapine, aripiprazole) for patients with first-episode schizophrenia during the first year of treatment. |
2020-12-31 |
2023-08-13 |
Not clear |
| Giuseppe Caruso, Margherita Grasso, Annamaria Fidilio, Fabio Tascedda, Filippo Drago, Filippo Carac. Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia. Pharmaceuticals (Basel, Switzerland). vol 13. issue 12. 2020-12-29. PMID:33322693. |
opposite to haloperidol, second-generation antipsychotics (or atypical antipsychotics) such as risperidone, clozapine, and olanzapine exert a strong antioxidant activity in experimental models of schizophrenia by rescuing the antioxidant system, with an increase in superoxide dismutase and glutathione (gsh) serum levels. |
2020-12-29 |
2023-08-13 |
Not clear |
| Matea Nikolac Perkovic, Marina Sagud, Maja Zivkovic, Suzana Uzun, Gordana Nedic Erjavec, Oliver Kozumplik, Dubravka Svob Strac, Ninoslav Mimica, Alma Mihaljevic Peles, Nela Piva. Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia. Scientific reports. vol 10. issue 1. 2020-12-10. PMID:32572118. |
the study assessed the association of the comt rs4680 and rs4818 polymorphisms with therapeutic response to olanzapine, risperidone, clozapine or other antipsychotic medication after 8 weeks of monotherapy in patients with schizophrenia. |
2020-12-10 |
2023-08-13 |
Not clear |
| Matea Nikolac Perkovic, Marina Sagud, Maja Zivkovic, Suzana Uzun, Gordana Nedic Erjavec, Oliver Kozumplik, Dubravka Svob Strac, Ninoslav Mimica, Alma Mihaljevic Peles, Nela Piva. Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia. Scientific reports. vol 10. issue 1. 2020-12-10. PMID:32572118. |
521 caucasian patients with schizophrenia received a monotherapy with olanzapine (10-20 mg/day; n = 190), risperidone (3-6 mg/day; n = 99), or clozapine (100-500 mg/day; n = 102). |
2020-12-10 |
2023-08-13 |
Not clear |
| Milica M Borovcanin, Slavica Minic Janicijevic, Ivan P Jovanovic, Nevena M Gajovic, Milena M Jurisevic, Nebojsa N Arsenijevi. Type 17 Immune Response Facilitates Progression of Inflammation and Correlates with Cognition in Stable Schizophrenia. Diagnostics (Basel, Switzerland). vol 10. issue 11. 2020-12-01. PMID:33182582. |
we included 27 patients diagnosed with schizophrenia (f20), after a three-month stable depot antipsychotic therapy (risperidone or paliperidone) and 18 healthy control subjects. |
2020-12-01 |
2023-08-13 |
human |
| Guangfei Li, Xiaowei Han, Wenwen Gao, Zeyu Song, Shuai Zhao, Feiyi Sun, Hong Ma, Ailing Cui, Xiaoying Tang, Guolin M. Influence of EGR3 Transfection on Imaging and Behavior in Rats and Therapeutic Effect of Risperidone in Schizophrenia Model. Frontiers in psychiatry. vol 11. 2020-11-17. PMID:33192626. |
influence of egr3 transfection on imaging and behavior in rats and therapeutic effect of risperidone in schizophrenia model. |
2020-11-17 |
2023-08-13 |
rat |
| Guangfei Li, Xiaowei Han, Wenwen Gao, Zeyu Song, Shuai Zhao, Feiyi Sun, Hong Ma, Ailing Cui, Xiaoying Tang, Guolin M. Influence of EGR3 Transfection on Imaging and Behavior in Rats and Therapeutic Effect of Risperidone in Schizophrenia Model. Frontiers in psychiatry. vol 11. 2020-11-17. PMID:33192626. |
we divided 34 rats into four groups: schizophrenia model group (e group), sham-operation group (fe group), healthy control group (h group), and risperidone therapy group (t group). |
2020-11-17 |
2023-08-13 |
rat |
| Guangfei Li, Xiaowei Han, Wenwen Gao, Zeyu Song, Shuai Zhao, Feiyi Sun, Hong Ma, Ailing Cui, Xiaoying Tang, Guolin M. Influence of EGR3 Transfection on Imaging and Behavior in Rats and Therapeutic Effect of Risperidone in Schizophrenia Model. Frontiers in psychiatry. vol 11. 2020-11-17. PMID:33192626. |
schizophrenia induced several neural alterations in alff and reho metrics of the rat brain, and risperidone could partly reverse these alterations. |
2020-11-17 |
2023-08-13 |
rat |
| Guangfei Li, Xiaowei Han, Wenwen Gao, Zeyu Song, Shuai Zhao, Feiyi Sun, Hong Ma, Ailing Cui, Xiaoying Tang, Guolin M. Influence of EGR3 Transfection on Imaging and Behavior in Rats and Therapeutic Effect of Risperidone in Schizophrenia Model. Frontiers in psychiatry. vol 11. 2020-11-17. PMID:33192626. |
the results suggest that similar research is required for schizophrenia and that risperidone may be a novel treatment for dysregulated neural activation in schizophrenia. |
2020-11-17 |
2023-08-13 |
rat |
| Martin Schaefer, Susanne Sarkar, Ines Theophil, Karolina Leopold, Andreas Heinz, Jürgen Gallina. Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. Pharmacopsychiatry. vol 53. issue 1. 2020-10-23. PMID:31390660. |
acute and long-term memantine add-on treatment to risperidone improves cognitive dysfunction in patients with acute and chronic schizophrenia. |
2020-10-23 |
2023-08-13 |
Not clear |
| Martin Schaefer, Susanne Sarkar, Ines Theophil, Karolina Leopold, Andreas Heinz, Jürgen Gallina. Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. Pharmacopsychiatry. vol 53. issue 1. 2020-10-23. PMID:31390660. |
in this proof-of-concept study we tested effects on cognition and negative symptoms of a 6- or 24-week memantine add-on treatment to risperidone in patients with acute or chronic schizophrenia. |
2020-10-23 |
2023-08-13 |
Not clear |
| Atefeh Bamarinejad, Shidrokh Nasiri, Fatemeh Bamarinejad, Rezvan Salehidoost, Elahe Zare-Farashband. Schizophrenia and Macroprolactinoma: Is There a Deep Link? Advanced biomedical research. vol 9. 2020-10-22. PMID:33072650. |
in the present case, we report a 29-year-old single male with schizophrenia who treated for 8 years with risperidone and presented with macroprolactinoma. |
2020-10-22 |
2023-08-13 |
Not clear |
| Zhenhe Zhou, Yuanyuan Zhu, Jun Wang, Hongmei Zh. Risperidone improves interpersonal perception and executive function in patients with schizophrenia. Neuropsychiatric disease and treatment. vol 13. 2020-10-01. PMID:28096678. |
risperidone improves interpersonal perception and executive function in patients with schizophrenia. |
2020-10-01 |
2023-08-13 |
Not clear |
| Zhenhe Zhou, Yuanyuan Zhu, Jun Wang, Hongmei Zh. Risperidone improves interpersonal perception and executive function in patients with schizophrenia. Neuropsychiatric disease and treatment. vol 13. 2020-10-01. PMID:28096678. |
to investigate whether risperidone improves social cognitive impairments and executive dysfunction in people with schizophrenia. |
2020-10-01 |
2023-08-13 |
Not clear |
| Ying Liang, Xin Y. The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study. Neuropsychiatric disease and treatment. vol 13. 2020-10-01. PMID:28461752. |
the effectiveness and safety of amisulpride in chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the escape study. |
2020-10-01 |
2023-08-13 |
Not clear |
| Ying Liang, Xin Y. The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study. Neuropsychiatric disease and treatment. vol 13. 2020-10-01. PMID:28461752. |
this subgroup analysis of the escape study evaluated the efficacy and safety of amisulpride in chinese patients with schizophrenia who switched from risperidone or olanzapine. |
2020-10-01 |
2023-08-13 |
Not clear |
| Sulochana Joshi, Rabi Shaky. Electroconvulsive Therapy in Functional Hallucination: Scope and Challenges. Case reports in psychiatry. vol 2017. 2020-10-01. PMID:29181215. |
we report on a female patient with paranoid schizophrenia who experienced functional hallucinations continuously despite the use of adequate risperidone, which controlled other symptoms. |
2020-10-01 |
2023-08-13 |
Not clear |
| Yezhe Lin, Yanmin Peng, Cuizhen Zhu, Yousong Su, Yuan Shi, Zhiguang Lin, Jinghong Chen, Donghong Cu. Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia. Shanghai archives of psychiatry. vol 29. issue 5. 2020-10-01. PMID:29276352. |
pretreatment serum mcp-1 level predicts response to risperidone in schizophrenia. |
2020-10-01 |
2023-08-13 |
Not clear |
| Hikaru Hori, Asuka Katsuki, Kiyokazu Atake, Reiji Yoshimur. Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study. Frontiers in psychiatry. vol 9. 2020-10-01. PMID:29568276. |
switching from risperidone to risperidone long-acting injection on cognitive function in stable schizophrenia patients: a pilot study. |
2020-10-01 |
2023-08-13 |
Not clear |
| Hikaru Hori, Asuka Katsuki, Kiyokazu Atake, Reiji Yoshimur. Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study. Frontiers in psychiatry. vol 9. 2020-10-01. PMID:29568276. |
the purpose of this study was to evaluate the effects of switching from oral risperidone to risperidone lai (rlai) on cognitive function in stable schizophrenia patients compared with the effects of continuing oral risperidone. |
2020-10-01 |
2023-08-13 |
Not clear |